Hydrogen sulfide protects against cisplatin-induced experimental nephrotoxicity in animal models: a systematic review and meta-analysis.

IF 2.3 3区生物学 Q2 MULTIDISCIPLINARY SCIENCES

PeerJ Pub Date : 2025-05-22 eCollection Date: 2025-01-01 DOI:10.7717/peerj.19481

Zhenyuan Han, Tianyu Deng, Dechao Yan, Yutao Jia, Jing Tang, Xiaoyan Wang

{"title":"Hydrogen sulfide protects against cisplatin-induced experimental nephrotoxicity in animal models: a systematic review and meta-analysis.","authors":"Zhenyuan Han, Tianyu Deng, Dechao Yan, Yutao Jia, Jing Tang, Xiaoyan Wang","doi":"10.7717/peerj.19481","DOIUrl":null,"url":null,"abstract":"Background: Cisplatin-induced acute kidney injury (cis-AKI) is not rare in oncological patients clinically, but there are limited prevention and treatment methods available. The efficacy of hydrogen sulfide (H2S) in mitigating cis-AKI has been studied and determined in animal models.Methods: According to the pre-registered program (PROSPERO: CRD 42023463779), we searched PubMed/Medline, Embase, and Web of Science databases using the keywords: hydrogen sulfide, cisplatin, acute kidney injury, and alternatives. A total of 13 articles met the inclusion criteria were included. Standardized mean difference (SMD) and 95% confidence interval (CI) were calculated and aggregated using random effects meta-analysis.Results: The results showed that H2S treatment significantly improved renal function (serum creatinine SMD = -2.96, 95% CI [-3.72 to -2.19], p < 0.00001; blood urea nitrogen SMD = -2.73, 95% CI [-3.68 to -1.78], p < 0.00001), decreased oxidative stress (superoxide dismutase SMD = 2.90, 95% CI [1.36-4.43], p = 0.0002) and inflammation levels (interleukin-1β SMD = -4.41, 95% CI [-5.84 to -2.97], p < 0.00001). However, there was a high degree of heterogeneity between studies (I2 > 70%). Further subgroup analysis did not show a clear source of the heterogeneity, but various H2S donors exhibited positive renal protection in those studies.Conclusions: H2S could be a new approach for treating cis-AKI, while the differential efficacies among natural and slow-release H2S donors remain to be compared and evaluated further. This meta-analysis may shed light on establishing preclinical and clinical investigation guidelines for treating human cis-AKI with H2S donors.","PeriodicalId":19799,"journal":{"name":"PeerJ","volume":"13 ","pages":"e19481"},"PeriodicalIF":2.3000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103845/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PeerJ","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.7717/peerj.19481","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cisplatin-induced acute kidney injury (cis-AKI) is not rare in oncological patients clinically, but there are limited prevention and treatment methods available. The efficacy of hydrogen sulfide (H₂S) in mitigating cis-AKI has been studied and determined in animal models.

Methods: According to the pre-registered program (PROSPERO: CRD 42023463779), we searched PubMed/Medline, Embase, and Web of Science databases using the keywords: hydrogen sulfide, cisplatin, acute kidney injury, and alternatives. A total of 13 articles met the inclusion criteria were included. Standardized mean difference (SMD) and 95% confidence interval (CI) were calculated and aggregated using random effects meta-analysis.

Results: The results showed that H₂S treatment significantly improved renal function (serum creatinine SMD = -2.96, 95% CI [-3.72 to -2.19], p < 0.00001; blood urea nitrogen SMD = -2.73, 95% CI [-3.68 to -1.78], p < 0.00001), decreased oxidative stress (superoxide dismutase SMD = 2.90, 95% CI [1.36-4.43], p = 0.0002) and inflammation levels (interleukin-1β SMD = -4.41, 95% CI [-5.84 to -2.97], p < 0.00001). However, there was a high degree of heterogeneity between studies (I² > 70%). Further subgroup analysis did not show a clear source of the heterogeneity, but various H₂S donors exhibited positive renal protection in those studies.

Conclusions: H₂S could be a new approach for treating cis-AKI, while the differential efficacies among natural and slow-release H₂S donors remain to be compared and evaluated further. This meta-analysis may shed light on establishing preclinical and clinical investigation guidelines for treating human cis-AKI with H₂S donors.

查看原文本刊更多论文

在动物模型中，硫化氢对顺铂诱导的实验性肾毒性具有保护作用：一项系统综述和荟萃分析。

背景：顺铂诱导的急性肾损伤（cis-AKI）在临床上并不罕见，但预防和治疗方法有限。在动物模型中研究并确定了硫化氢（H2S）减轻顺式aki的功效。方法：根据预注册项目（PROSPERO: CRD 42023463779），检索PubMed/Medline、Embase和Web of Science数据库，检索关键词：硫化氢、顺铂、急性肾损伤和替代品。共纳入13篇符合纳入标准的文章。标准化平均差（SMD）和95%置信区间（CI）采用随机效应荟萃分析计算和汇总。结果：结果显示，H2S治疗显著改善肾功能(血清肌酐SMD = -2.96, 95% CI [-3.72 ~ -2.19], p < 0.00001；血尿素氮SMD = -2.73, 95% CI [-3.68 ~ -1.78], p < 0.00001)，降低氧化应激（超氧化物歧化酶SMD = 2.90, 95% CI [1.36 ~ 4.43], p = 0.0002）和炎症水平（白细胞介素-1β SMD = -4.41, 95% CI [-5.84 ~ -2.97], p < 0.00001）。然而，研究之间存在高度的异质性（I2 ~ 70%）。进一步的亚组分析没有显示出异质性的明确来源，但在这些研究中，各种H2S供者表现出积极的肾保护作用。结论：H2S可能是治疗顺式aki的新方法，而天然和缓释H2S供体的疗效差异仍有待进一步比较和评估。该荟萃分析可能有助于建立治疗H2S供体的人类顺性aki的临床前和临床研究指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PeerJ MULTIDISCIPLINARY SCIENCES-

CiteScore

4.70

自引率

3.70%

发文量

1665

审稿时长

10 weeks

期刊介绍： PeerJ is an open access peer-reviewed scientific journal covering research in the biological and medical sciences. At PeerJ, authors take out a lifetime publication plan (for as little as $99) which allows them to publish articles in the journal for free, forever. PeerJ has 5 Nobel Prize Winners on the Board; they have won several industry and media awards; and they are widely recognized as being one of the most interesting recent developments in academic publishing.